SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.

Key facts

Study ID

NCT04861415

Run by

Dr. Gerard Morton

People needed

55

Starts

2020-12-23

Expected to finish

2027-12-23

Last updated by the study team

2023-04-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Informed consent for treatment and study participation completed
• Pathologically proven diagnosis of prostate adenocarcinoma
• ECOG Performance Status 0-2
• No prior history of pelvic radiotherapy, brachytherapy, cryosurgery, HIFU, TURP or radical prostatectomy

You may not qualify if…

• Presence of nodal or distant metastasis on staging MRI or CT Abdomen/Pelvis and Bone scan within 90 days of enrolment (CT/MRI/Bone Scan are only required if the clinical risk of metastatic disease is sufficient to warrant these scans)
• Plan for adjuvant chemotherapy post-radiotherapy
• Serious medical comorbidities or other contraindications to HDR brachytherapy
• Presence of inflammatory bowel disease
• Presence of connective tissue disorder seen as a contraindication to radiotherapy
• Medically unfit for general/spinal anesthesia
• Unable or unwilling to complete questionnaires

Where it is running

• Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.